Ovid Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

OVID$2.80-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)	For The Three Months EndedSeptember 30, 2025	For The Three Months EndedSeptember 30, 2024	For The Nine Months EndedSeptember 30, 2025	For The Nine Months EndedSeptember 30, 2024
Revenue:
License and other revenue	$132	$173	$6,534	$490
Total revenue	132	173	6,534	490
Operating expenses:
Research and development	5,870	7,855	18,993	30,844
General and administrative	6,785	5,544	17,687	20,809
Total operating expenses	12,655	13,399	36,680	51,653
Loss from operations	(12,523)	(13,226)	(30,146)	(51,163)
Other income (expense), net	365	(780)	3,069	33,983
Loss before provision for income taxes	(12,158)	(14,006)	(27,077)	(17,180)
Provision for income taxes	—	—	—	—
Net loss	$(12,158)	$(14,006)	$(27,077)	$(17,180)
Net loss per share of Series A preferred stock, basic and diluted	$(168.01)	$(193.92)	$(374.30)	$(238.21)
Weighted-average Series A preferred stock shares outstanding, basic and diluted	1,250	1,250	1,250	1,250
Net loss per share of common stock, basic and diluted	$(0.17)	$(0.20)	$(0.37)	$(0.24)
Weighted-average common stock shares outstanding, basic and diluted	71,114,181	70,975,785	71,090,052	70,870,224

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.